Inappropriate sinus tachycardia: focus on ivabradine

Inappropriate sinus tachycardia (IST) is an incompletely understood condition, characterised by an elevation in heart rate (HR) accompanied by wide ranging symptoms in the absence of an underlying physiological stimulus. The condition often takes a chronic course with significant adverse effects on...

Full description

Saved in:
Bibliographic Details
Published in:Internal medicine journal 2016-08, Vol.46 (8), p.875-883
Main Authors: Abed, H. S., Fulcher, J. R., Kilborn, M. J., Keech, A. C.
Format: Article
Language:English
Subjects:
Adrenergic beta-Antagonists - therapeutic use
Benzazepines - adverse effects
Benzazepines - therapeutic use
Cardiovascular Agents - adverse effects
Cardiovascular Agents - therapeutic use
Diagnosis, Differential
Disease Management
Electrocardiography, Ambulatory
Heart Rate - drug effects
Humans
inappropriate sinus tachycardia
ivabradine
Practice Guidelines as Topic
Quality of Life
Randomized Controlled Trials as Topic
Tachycardia, Sinus - diagnosis
Tachycardia, Sinus - drug therapy
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inappropriate sinus tachycardia (IST) is an incompletely understood condition, characterised by an elevation in heart rate (HR) accompanied by wide ranging symptoms in the absence of an underlying physiological stimulus. The condition often takes a chronic course with significant adverse effects on quality of life. Currently, there is no effective treatment for IST. Beta‐blockers, generally considered the cornerstone of treatment, are often ineffective and poorly tolerated. Ivabradine is a novel sinus node If ‘funny current’ inhibitor, which reduces the HR. It has been approved for the treatment of beta‐blocker refractory chronic systolic heart failure and chronic stable angina but more recently has shown promise in the treatment of IST. This review provides an overview of IST prevalence and mechanisms followed by an examination of the evidence for the role and efficacy of ivabradine in the treatment of IST.
ISSN:1444-0903
1445-5994
DOI:10.1111/imj.13093